Company:  NEUROCRINE BIOSCIENCES IN ... (NBIX)
Form Type:  10-Q
Filing Date:  7/26/2013 
CIK:  0000914475 
Address:  12780 EL CAMINO REAL 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 617-7600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$13.79  
Change: 
0.01 (0.07%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$1.05B
Description of Business
We were originally incorporated in California in January 1992 and were reincorporated in Delaware in May 1996. We discover and develop innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through our novel R&D platform, focused on neurological and endocrine based diseases and disorders. Our two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women�s health that is partnered with AbbVie Inc. (AbbVie), and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. We intend to maintain certain commercial rights to our VMAT2 inhibitor and evolve into a fully-integrated pharmaceutical company.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        CASH FLOW
        NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II: OTHER INFORMATION
      ITEM 1A. RISK FACTORS
      ITEM 6. EXHIBITS
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
  EXHIBIT 32
    CERTIFICATIONS OF
BROKERAGE PARTNERS